Cellebrite: Improving Fundamentals Make a Case to Buy into Digital-Forensics Growth
Cellebrite (CLBT) has shown consistent revenue growth, an expanding market opportunity in digital evidence management, and recent insider/institutional confidence. At a $3.16B market cap and modest operational scale, the stock looks actionable from current levels for a long-term trade with defined risk controls.